Dashboard
Manage Tickers

BLCO Bausch & Lomb Corp

NYSE bausch.com


$ 14.88 $ 0.04 (0.27 %)    

Friday, 17-Oct-2025 11:47:24 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 599.31 $ 1.76 (0.29 %)
DIA $ 460.34 $ 0.98 (0.21 %)
SPY $ 660.51 $ 1.06 (0.16 %)
TLT $ 91.23 $ 0.01 (0.01 %)
GLD $ 391.14 $ -6.08 (-1.53 %)
$ 14.86
$ 14.84
$ 14.84 x 100
$ 14.88 x 14
$ 14.88 - $ 14.93
$ 10.45 - $ 21.08
290,502
na
5.26B
$ 0.71
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 07-30-2025 06-30-2025 10-Q
2 04-30-2025 03-31-2025 10-Q
3 02-19-2025 12-31-2024 10-K
4 10-30-2024 09-30-2024 10-Q
5 08-01-2024 06-30-2024 10-Q
6 05-01-2024 03-31-2024 10-Q
7 02-21-2024 12-31-2023 10-K
8 11-01-2023 09-30-2023 10-Q
9 08-02-2023 06-30-2023 10-Q
10 05-03-2023 03-31-2023 10-Q
11 02-22-2023 12-31-2022 10-K
12 11-02-2022 09-30-2022 10-Q
13 08-04-2022 06-30-2022 10-Q
14 06-08-2022 03-31-2022 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

evercore-isi-group-maintains-outperform-on-bausch--lomb-raises-price-target-to-17
Evercore ISI Group Maintains Outperform on...
10/07/2025 16:32:12

Evercore ISI Group analyst Vijay Kumar maintains Bausch & Lomb (NYSE:BLCO) with a Outperform and raises the price target...

goldman-sachs-initiates-coverage-on-bausch--lomb-with-neutral-rating-announces-price-target-of-16
Goldman Sachs Initiates Coverage On Bausch...
10/01/2025 17:50:40

Goldman Sachs analyst David Roman initiates coverage on Bausch & Lomb (NYSE:BLCO) with a Neutral rating and announces Pr...

bausch--lomb-reports-envista-envy-intraocular-lens-met-all-primary-efficacy-and-safety-endpoints-in-multicenter-us-study
Bausch + Lomb Reports enVista Envy Intraoc...
09/11/2025 11:04:24

enVista Envy full range of vision intraocular lens (IOL) met all primary efficacy and safety endpoints in multicenter studyResu...

Core News & Articles
Bausch + Lomb Study Shows XIIDRA 5% Eases ...
09/09/2025 11:18:51

XIIDRA significantly improved end-of-day eye dryness and discomfort and delivered longer comfortable contact lens wear time in ...

Core News & Articles
Bausch + Lomb Announces U.S. Launch Of ASA...
09/08/2025 11:09:46

ASANA offers a comprehensive, customizable gas permeable portfolio including spherical, aspheric, toric, multifocal, reverse ge...

morgan-stanley-maintains-equal-weight-on-bausch--lomb-raises-price-target-to-13
Morgan Stanley Maintains Equal-Weight on B...
08/01/2025 14:11:13

Morgan Stanley analyst Patrick Wood maintains Bausch & Lomb (NYSE:BLCO) with a Equal-Weight and raises the price target ...

hc-wainwright--co-maintains-buy-on-bausch--lomb-raises-price-target-to-16
HC Wainwright & Co. Maintains Buy on Bausc...
07/31/2025 17:25:47

HC Wainwright & Co. analyst Yi Chen maintains Bausch & Lomb (NYSE:BLCO) with a Buy and raises the price target from ...

wells-fargo-maintains-equal-weight-on-bausch--lomb-raises-price-target-to-15
Wells Fargo Maintains Equal-Weight on Baus...
07/31/2025 15:39:37

Wells Fargo analyst Larry Biegelsen maintains Bausch & Lomb (NYSE:BLCO) with a Equal-Weight and raises the price target ...

bausch--lomb-raises-fy2025-sales-guidance-from-5000b-5100b-to-5050b-5150b-vs-5024b-est
Bausch & Lomb Raises FY2025 Sales Guidance...
07/30/2025 11:06:19

Bausch & Lomb (NYSE:BLCO) raises FY2025 sales outlook from $5.000 billion-$5.100 billion to $5.050 billion-$5.150 billion v...

bausch--lomb-q2-adj-eps-007-inline-sales-1278b-beat-1255b-estimate
Bausch & Lomb Q2 Adj. EPS $0.07, Inline, S...
07/30/2025 11:00:34

Bausch & Lomb (NYSE:BLCO) reported quarterly earnings of $0.07 per share which met the analyst consensus estimate. This is ...

Core News & Articles
Earnings Scheduled For July 30, 2025
07/30/2025 08:32:48

examining-the-future-bausch--lombs-earnings-outlook
Examining the Future: Bausch & Lomb's Earn...
07/29/2025 19:02:29

bausch-health-adds-late-stage-ready-alcohol-liver-disease-drug-candidate-in-63-million-durect-buyout
Bausch Health Adds Late-Stage Ready Alcoho...
07/29/2025 18:21:25

Bausch Health will acquire DURECT and larsucosterol, aiming for FDA approval of a first treatment for alcoholic hepatitis via P...

bausch--lomb-says-ophthalmology-and-therapy-publishes-results-from-phase-3-study-assessing-efficacy-safety-of-lumify-preservative-free-redness-reliever-eye-drops-versus-lumify-redness-reliever-eye-drops-for-reducing-ocular-redness
Bausch + Lomb Says Ophthalmology And Thera...
07/29/2025 11:25:35

bausch--lomb-publishes-phase-3-data-confirming-lumify-preservative-free-eye-drops-match-original-lumify-in-safety-efficacy-and-8-hour-redness-relief
Bausch + Lomb Publishes Phase 3 Data Confi...
07/29/2025 11:15:43

deal-dispatch-del-taco-tanks-tylenol-maker-aches-for-change-joyebells-burns-the-pie
Deal Dispatch: Del Taco Tanks, Tylenol Mak...
07/18/2025 17:36:32

This week's M&A news includes strategic pivots and stumbles galore, with updates from WK Kellogg, Matador Restaurant an...

evercore-isi-group-maintains-outperform-on-bausch--lomb-raises-price-target-to-16
Evercore ISI Group Maintains Outperform on...
07/08/2025 12:49:53

Evercore ISI Group analyst Vijay Kumar maintains Bausch & Lomb (NYSE:BLCO) with a Outperform and raises the price target...

bausch--lomb-uses-survey-insights-and-patient-input-to-clarify-dry-eye-realities
Bausch + Lomb Uses Survey Insights And Pat...
07/01/2025 11:10:21

Core News & Articles
Bausch + Lomb Subsidiaries Launch Offering...
06/10/2025 12:50:19

Bausch + Lomb Corporation (TSX:BLCO) ("Bausch + Lomb" or the "company"), a leading global eye health company de...

barclays-maintains-equal-weight-on-bausch--lomb-lowers-price-target-to-16
Barclays Maintains Equal-Weight on Bausch ...
06/09/2025 15:58:14

Barclays analyst Matt Miksic maintains Bausch & Lomb (NYSE:BLCO) with a Equal-Weight and lowers the price target from $1...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION